October 19, 2022
Life Sciences
  • The Kaiser Family Foundation released a brief examining how accessibility and cost of COVID-19 vaccines, treatments, and tests will change after the public health emergency (PHE) ends and such countermeasure efforts shift to the commercial market. The brief points out that it is uncertain if manufacturers will be incentivized to produce enough vaccines, tests, and treatments without the security of government purchases. Even if there is a sufficient supply of products, people who are uninsured or underinsured will not have coverage and those with insurance could face new or higher cost-sharing. (Brief here)